Clinical Trial

Cord Blood Transplant in Adults With Blood Cancers

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Cord blood transplants (CBT) are a standard treatment for adults with blood cancers. MSK has developed a standard ("optimized") practice for cord blood transplant (CBT). This optimized practice includes how patients are evaluated for transplant, the conditioning treatment (standard chemotherapy and total body irradiation therapy) given to prepare the body for transplant, the amount of stem cells transplanted, and how patients are followed during and after transplant.The purpose of this study is to collect information about participant outcomes after CBT following MSK's optimized practice. The researchers will look at outcomes of the CBT treatment such as side effects, disease relapse, GVHD, and immune system recovery after CBT treatment.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2023-05-22; most recent amendment 2025-09-05.
Trial Details
NCT Number NCT05884333
Lead Sponsor Memorial Sloan Kettering Cancer Center
Conditions Acute Myelogenous Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Chronic Myelogenous Leukemia (CML), Myelodysplastic Syndromes (MDS), Myeloproliferative Disorder, Non-Hodgkin's Lymphoma
Enrollment 54 participants
Start Date 2023-05-22
Primary Completion 2028-05-22 (estimated)
Study Completion 2028-05-22 (estimated)
Updated on ClinicalTrials.gov 2025-09-08